Scientific Reports, Volume 10, Issue 1 , 01/12/2020

Characterization of extended-spectrum-β-lactamase producing Klebsiella pneumoniae phage KP1801 and evaluation of therapeutic efficacy in vitro and in vivo

Phitchayapak Wintachai, Ampapan Naknaen, Jirapath Thammaphet, Rattanaruji Pomwised, Narumon Phaonakrop, Sittiruk Roytrakul, Duncan R. Smith

Abstract

Extended spectrum β lactamase-producing Klebsiellapneumoniae (ESBL-KP) is being reported with high morbidity and mortality rates and is considered as the highest priority for new antimicrobial strategies. To develop an alternative antimicrobial agent, phage KP1801 with broad lytic activity was isolated. The genome of phage KP1801 was double stranded DNA of 49,835 base pairs, with a GC content of 50.26%. There were 75 putative open reading frames. Phage KP1801 was classified as being in the order Caudovirales, belonging to the Siphoviridae family. About 323 proteins were detected by shotgun proteome analysis. The phage inhibited biofilm formation and reduced pre-formed biofilm in a dose dependent manner. Scanning electron microscopic studies demonstrated a membrane damage of bacterial cells treated with phage, resulting in cell death. Prophylactic and therapeutic efficacies of the phage were evaluated in Galleriamellonella. Administration of ESBL-KP infection with phage significantly improved the survival of G.mellonella. The number of intracellular bacteria in larvae showed a significant decrease compared with untreated control while the number of phage increased. These studies suggested that phage KP1801 has the potential for development as an alternative for antibiotics and biocontrol agents against ESBL-KP infection.

Document Type

Article

Source Type

Journal

ASJC Subject Area

Multidisciplinary : Multidisciplinary

Funding Agency

Thailand Research Fund


Bibliography


Wintachai, P., Naknaen, A., Thammaphet, J., Pomwised, R., Phaonakrop, N., Roytrakul, S., & Smith, D. (2020). Characterization of extended-spectrum-β-lactamase producing Klebsiella pneumoniae phage KP1801 and evaluation of therapeutic efficacy in vitro and in vivo. Scientific Reports, 10(1) doi:10.1038/s41598-020-68702-y

Copy | Save